Cyclacel Pharmaceuticals (CYCC) Short Interest Ratio & Short Volume $0.50 -0.12 (-19.20%) (As of 11/4/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Cyclacel Pharmaceuticals Short Interest DataCyclacel Pharmaceuticals (CYCC) has a short interest of 36,500 shares, representing 1.78% of the float (the number of shares available for trading by the public). This marks a -23.80% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 624,291 shares to cover all short positions.Current Short Interest36,500 sharesPrevious Short Interest47,900 sharesChange Vs. Previous Month-23.80%Dollar Volume Sold Short$31,390.00Short Interest Ratio0.0 Days to CoverLast Record DateOctober 15, 2024Outstanding Shares2,151,000 sharesFloat Size2,050,000 sharesShort Percent of Float1.78%Today's Trading Volume655,682 sharesAverage Trading Volume624,291 sharesToday's Volume Vs. Average105% Short Selling Cyclacel Pharmaceuticals? Sign up to receive the latest short interest report for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCYCC Short Interest Over TimeCYCC Days to Cover Over TimeCYCC Percentage of Float Shorted Over Time Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Cyclacel Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/202436,500 shares $31,390.00 -23.8%1.8%0 $0.86 9/30/202447,900 shares $47,421.00 +0.6%2.5%0.8 $0.99 9/15/202447,600 shares $48,076.00 -14.9%2.5%0.7 $1.01 8/31/202455,900 shares $58,806.80 +3.0%3.0%0.7 $1.05 8/15/202454,300 shares $71,676.00 -18.6%2.9%0.4 $1.32 7/31/202466,700 shares $112,056.00 -41.0%4.9%0.5 $1.68 Get the Latest News and Ratings for CYCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/15/2024113,100 shares $196,794.00 -32.4%8.3%0.1 $1.74 6/30/2024167,300 shares $271,026.00 +8.1%12.2%0.2 $1.62 6/15/2024154,700 shares $261,443.00 +63.7%11.3%0.2 $1.69 5/31/202494,500 shares $249,480.00 -35.0%6.9%0.1 $2.64 5/15/2024145,300 shares $354,532.00 -58.6%10.6%0.2 $2.44 4/30/2024351,100 shares $744,332.00 +814.3%29.3%0.5 $2.12 4/15/202438,400 shares $60,672.00 +58.0%3.2%0.8 $1.58 3/31/202424,300 shares $51,270.57 -8.7%2.0%0.2 $2.11 3/15/202426,600 shares $64,638.00 -35.9%2.2%0.2 $2.43 2/29/202441,500 shares $106,240.00 -44.5%3.6%0.2 $2.56 2/15/202474,800 shares $198,968.00 -10.0%6.4%0.5 $2.66 1/31/202483,100 shares $186,144.00 +0.7%9.3%0.5 $2.24 1/15/202482,500 shares $194,700.00 +129.2%9.1%0.6 $2.36 12/31/202336,000 shares $96,120.00 -13.3%4.0%0.3 $2.67 12/15/202341,500 shares $148,466.25 -92.2%5.9%1.3 $3.58 11/30/2023530,900 shares $159,270.00 +2.5%5.0%3 $0.30 11/15/2023518,200 shares $179,297.20 +1.2%4.9%3.6 $0.35 10/31/2023512,300 shares $275,924.78 +1.1%4.8%4.1 $0.54 10/15/2023506,900 shares $316,305.60 +3.7%4.7%4.3 $0.62 9/30/2023488,800 shares $173,377.36 +7.1%4.5%5.2 $0.35 9/15/2023456,600 shares $148,349.34 +7.0%4.2%4.9 $0.32 8/31/2023426,900 shares $169,052.40 +4.9%4.0%4.3 $0.40 8/15/2023406,800 shares $190,382.40 -7.6%3.8%5.4 $0.47 7/31/2023440,100 shares $294,426.90 -0.5%4.1%6.3 $0.67 7/15/2023442,100 shares $259,114.81 +1.5%4.1%6.1 $0.59 6/30/2023435,400 shares $256,494.14 -1.8%4.0%7.7 $0.59 6/15/2023443,400 shares $297,477.06 -12.7%4.1%7.5 $0.67 5/31/2023508,000 shares $325,120.00 +5.5%4.7%9.9 $0.64 5/15/2023481,400 shares $260,629.96 No Change4.4%8.1 $0.54 10/31/2022461,800 shares $641,902.00 +15.6%N/A0.9 $1.39 10/15/2022399,400 shares $519,220.00 -15.6%N/A0.6 $1.30 9/30/2022473,000 shares $690,580.00 +16.7%N/A0.5 $1.46 9/15/2022405,500 shares $640,690.00 -44.1%N/A0.4 $1.58 8/31/2022725,400 shares $1.22 million -43.8%N/A0.6 $1.68The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. 8/15/20221,290,000 shares $2.04 million +50.6%N/A1.1 $1.58 7/31/2022856,400 shares $976,296.00 +46.7%N/A1.1 $1.14 7/15/2022583,900 shares $712,358.00 +147.5%N/A0.9 $1.22 6/30/2022235,900 shares $254,772.00 -5.5%2.6%0.5 $1.08 6/15/2022249,500 shares $279,440.00 +10.0%2.8%0.9 $1.12 5/31/2022226,800 shares $272,160.00 -18.6%2.8%1.1 $1.20 5/15/2022278,500 shares $387,115.00 -23.9%3.4%2.1 $1.39 4/30/2022366,100 shares $684,607.00 -21.0%4.5%3 $1.87 4/15/2022463,600 shares $950,380.00 +53.4%5.7%3.7 $2.05 3/31/2022302,200 shares $921,710.00 -5.1%N/A7.2 $3.05 3/15/2022318,500 shares $863,135.00 -4.7%3.9%4.9 $2.71 2/28/2022334,100 shares $1.09 million -5.8%4.1%4.6 $3.25 2/15/2022354,500 shares $1.31 million -11.7%4.3%4.3 $3.69 1/31/2022401,300 shares $1.28 million -3.2%4.9%4.4 $3.18 1/15/2022414,400 shares $1.50 million +17.1%5.1%4.6 $3.62 12/31/2021353,800 shares $1.38 million -3.4%4.3%3.8 $3.89 12/15/2021366,200 shares $1.23 million -14.1%4.5%3.5 $3.36 11/30/2021426,100 shares $1.53 million -12.7%5.3%3.8 $3.58 11/15/2021488,300 shares $2.33 million -4.0%6.1%4.2 $4.78 10/29/2021508,600 shares $2.50 million -0.6%6.8%4.4 $4.91 10/15/2021511,600 shares $2.85 million -2.2%6.9%4.2 $5.57 9/30/2021523,300 shares $2.76 million +3.1%7.0%4.2 $5.27 9/15/2021507,400 shares $3.00 million +6.4%6.8%5.1 $5.91 8/31/2021476,800 shares $2.59 million -2.5%6.4%5.4 $5.44 8/13/2021488,800 shares $2.40 million -14.8%6.6%5.7 $4.90 7/30/2021573,900 shares $2.85 million -20.0%7.7%6 $4.96 7/15/2021717,600 shares $3.79 million -9.9%9.7%6.4 $5.28 6/30/2021796,400 shares $4.71 million +22.1%10.7%6.7 $5.92 6/15/2021652,200 shares $4.36 million -26.7%8.8%4.9 $6.69 5/28/2021890,200 shares $6.38 million +3.1%12.0%4.6 $7.17 5/14/2021863,800 shares $5.67 million +5.2%12.0%3.2 $6.56 4/30/2021821,000 shares $5.84 million -4.1%11.4%1.6 $7.11 4/15/2021856,300 shares $6.02 million -0.2%N/A0 $7.03 3/31/2021858,100 shares $5.73 million -11.3%13.6%1.2 $6.68 3/15/2021967,900 shares $7.31 million -7.8%15.4%1 $7.55 2/26/20211,050,000 shares $7.35 million +1.9%29.2%1.2 $7.00 2/12/20211,030,000 shares $9.98 million +26.4%28.6%1.2 $9.69 1/29/2021814,600 shares $6.19 million -16.2%16.2%1.1 $7.60 1/15/2021972,300 shares $8.76 million +9.6%19.3%2.2 $9.01 12/31/2020887,400 shares $6.34 million +319.2%17.7%2.1 $7.15 12/15/2020211,700 shares $908,193.00 +221.7%4.0%0.6 $4.29 11/30/202065,800 shares $253,330.00 -9.5%1.4%0.4 $3.85 11/15/202072,700 shares $257,358.00 -16.1%1.5%0.6 $3.54 10/30/202086,600 shares $296,172.00 +166.5%1.8%0.5 $3.42 10/15/202032,500 shares $134,062.50 -39.3%0.7%0.2 $4.13 9/30/202053,500 shares $195,275.00 +87.1%1.1%0.2 $3.65 9/15/202028,600 shares $98,670.00 -2.7%0.6%0.1 $3.45 8/31/202029,400 shares $112,308.00 -84.9%0.6%0.1 $3.82 8/14/2020194,300 shares $872,407.00 +50.9%4.0%0.6 $4.49 7/31/2020128,800 shares $637,560.00 -38.2%2.7%0.2 $4.95The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. 7/15/2020208,500 shares $925,740.00 -10.8%4.3%0.3 $4.44 6/30/2020233,800 shares $1.08 million +6.1%4.9%0.3 $4.64 6/15/2020220,400 shares $996,208.00 -35.6%4.6%0.3 $4.52 5/29/2020342,200 shares $1.85 million +295.2%7.1%0.4 $5.40 5/15/202086,600 shares $355,926.00 -30.9%1.8%0.1 $4.11 4/30/2020125,400 shares $522,918.00 +1,040.0%15.1%0.3 $4.17 4/15/202011,000 shares $87,670.00 -92.2%1.3%0 $7.97 3/31/2020141,700 shares $569,634.00 +243.1%0.8%0.8 $4.02 3/13/202041,300 shares $16,107.00 +144.4%0.2%0.3 $0.39 2/28/202016,900 shares $5,577.00 -79.9%0.1%0.1 $0.33 2/14/202084,100 shares $40,368.00 -50.5%0.5%0.3 $0.48 1/31/2020169,900 shares $103,639.00 -43.2%1.0%0.7 $0.61 1/15/2020298,900 shares $215,208.00 -30.2%1.8%1.2 $0.72 12/31/2019427,900 shares $325,204.00 +30.5%2.5%1.9 $0.76 CYCC Short Interest - Frequently Asked Questions What is Cyclacel Pharmaceuticals' current short interest? Short interest is the volume of Cyclacel Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 15th, investors have sold 36,500 shares of CYCC short. 1.78% of Cyclacel Pharmaceuticals' shares are currently sold short. Learn More on Cyclacel Pharmaceuticals' current short interest. What is a good short interest percentage for Cyclacel Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.78% of Cyclacel Pharmaceuticals' floating shares are currently sold short. Is Cyclacel Pharmaceuticals' short interest increasing or decreasing? Cyclacel Pharmaceuticals saw a decline in short interest in October. As of October 15th, there was short interest totaling 36,500 shares, a decline of 23.8% from the previous total of 47,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cyclacel Pharmaceuticals' float size? Cyclacel Pharmaceuticals currently has issued a total of 2,151,000 shares. Some of Cyclacel Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cyclacel Pharmaceuticals currently has a public float of 2,050,000 shares. How does Cyclacel Pharmaceuticals' short interest compare to its competitors? 1.78% of Cyclacel Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cyclacel Pharmaceuticals: Sonoma Pharmaceuticals, Inc. (6.05%), Orgenesis Inc. (0.29%), Shuttle Pharmaceuticals Holdings, Inc. (1.67%), Jaguar Health, Inc. (1.81%), Biomerica, Inc. (2.22%), Hoth Therapeutics, Inc. (4.58%), Eagle Pharmaceuticals, Inc. (2.90%), Creative Medical Technology Holdings, Inc. (2.28%), BioCardia, Inc. (1.84%), Genprex, Inc. (3.51%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short Cyclacel Pharmaceuticals stock? Short selling CYCC is an investing strategy that aims to generate trading profit from Cyclacel Pharmaceuticals as its price is falling. CYCC shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cyclacel Pharmaceuticals? A short squeeze for Cyclacel Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CYCC, which in turn drives the price of the stock up even further. How often is Cyclacel Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYCC, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies Sonoma Pharmaceuticals Short Interest Data Orgenesis Short Interest Data Shuttle Pharmaceuticals Short Interest Data Jaguar Health Short Interest Data Biomerica Short Interest Data Hoth Therapeutics Short Interest Data Eagle Pharmaceuticals Short Interest Data Creative Medical Technology Short Interest Data BioCardia Short Interest Data Genprex Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CYCC) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
